Business Wire

Philip Morris International Organizes for Continued Innovation: Deepak Mishra Named President, Americas Region, Martin King to Retire After 30 Years of Service

Share

Jacek Olczak, Chief Executive Officer of Philip Morris International (PMI) (NYSE: PM), today announced a new structure for the Americas with the appointment of Deepak Mishra—formerly Chief Strategy Officer—as President, Americas Region, covering the United States, Canada, and Latin America. The appointment is effective July 1.

The new structure in the Americas will focus on three areas: strengthening PMI’s leadership in Latin America & Canada as the company accelerates toward a smoke-free future; deepening efforts with partners to commercialize reduced risk products in the U.S.; and building a vital launchpad for the company’s “beyond nicotine” strategy in the U.S., in coordination with PMI’s Life Sciences group, through expanded partnerships and commercial deployment.

Mr. Olczak said, “I am thrilled to name Deepak Mishra, one of our top business leaders, to one of the most important roles for the future of our company. In less than three years with PMI, he has been instrumental in shaping our long-term strategy and bringing it to life through strategic partnerships and investments. Deepak brings to the role deep expertise in mergers and acquisitions, a likely component of our beyond nicotine strategy. He is both a visionary and a pragmatist, and I have high expectations for—and full confidence in—what he will accomplish in his new role.”

Prior to joining PMI, Mr. Mishra was Managing Director, Portfolio Operations at Centerbridge Partners LP, a private equity firm, where, from 2014, he led commercial, operational, and digital transformations in investments in consumer services, renewable energy, and distribution sectors. Before Centerbridge, Mr. Mishra was a Partner at McKinsey & Company in London. At McKinsey & Company he was a member of the Consumer Goods, Retail, and Operations leadership teams from 2001 to 2014 and supported clients in the fast-moving consumer goods, retail, and private equity industries on commercial and operational transformations. Mr. Mishra started his career as a marketing professional with Procter & Gamble in 1996 and then spent four years at Accenture’s strategy practice in India and Eastern Europe. He holds an undergraduate degree in computer science from BITS Pilani in India and an MBA from the Indian Institute of Management (IIM) Lucknow.

Mr. Mishra’s direct reports will include Mario Masseroli, President, Latin America Region; Peter Luongo, Managing Director of Rothmans, Benson & Hedges (Canada); and Olek Grzesiak, Vice President, Commercial for Reduced Risk Products in the United States. The Washington, D.C.–based External Affairs team, led by attorney J.B. Simko, will report to Gregoire Verdeaux, Senior Vice President, External Affairs. Other corporate functions domiciled in the U.S. will continue to report to their corporate leads.

Martin King, who has been with PMI since 2003, most recently as CEO, PMI America, and before this as Chief Financial Officer, President of its Asia Region, President of its Latin America and Canada Region, and Senior Vice President of Operations, will retire on August 31, 2021. Prior to joining PMI, Mr. King served in various positions within Philip Morris USA—part of PMI’s former parent company—between 1991 and 2003. Mr. Olczak noted, “We are deeply grateful to Martin King for his many years and many accomplishments at PMI, and for the impact he has had in the U.S. in the year he spent getting the market ready for the push we plan to make in bringing both reduced-risk and, eventually, beyond nicotine products to consumers. Martin is an outstanding business leader and colleague, and we wish him the very best in the years to come.”

Also from July 1, PMI’s Strategy & Program Delivery function, which formerly reported to Mr. Mishra, will report to Chief Financial Officer Emmanuel Babeau. Ankur Modi will assume the position of Global Head, Strategy & Program Delivery. On August 1, Reginaldo Dobrowolski will take on the role of Vice President and Controller, and Andreas Kurali will become Deputy CFO, Finance Transformation.

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders, and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI’s smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Philip Morris International
David Fraser
T. +41 (0)79 843 8603
E. david.fraser@pmi.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release

Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye